Antibody–drug conjugates combined with immune checkpoint inhibitors in cancer: mechanisms, clinical evidence, and translational challenges

Immune checkpoint inhibitors (ICIs) have become an important component of cancer therapy, but primary resistance, acquired resistance, cold or immune-excluded tumor states, and immune-related adverse events continue to limit durable benefit. Antibody-drug conjugates (ADCs), while designed for targeted delivery of cytotoxic payloads, may also influence tumor cell death, antigen release, and local immune responses, providing a drug-design rationale for combination strategies with immunotherapy. Mechanistically, intratumoral ADC exposure and immune effects are shaped by the antibody, linker, payload, target internalization, and bystander effect, with implications for immunogenic cell death (ICD), the release of damage-associated molecular patterns (DAMPs), activation of cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling and Toll-like receptor (TLR) signaling, and remodeling of the tumor immune microenvironment (TIME). Clinical studies now span urothelial cancer, breast cancer, gynecologic malignancies, hematologic malignancies, lung cancer, and gastrointestinal cancers; interpretation of these findings requires attention to cancer type, target expression, payload class, treatment line, prior ICI exposure, and study design. Target heterogeneity, peripheral immune status, organ function, and comorbidities may further affect efficacy interpretation, toxicity attribution, and subsequent treatment selection. Further clinical translation should integrate biomarker development and patient stratification with resistance mechanisms, sequential therapy, quality of life, and treatment affordability, so that regimen design, patient selection, and safety management can be evaluated more clearly in prospective studies.

Authors

Institutions

Publication Details

Journal
Molecular Cancer
Published
2026-11-13
DOI
https://doi.org/10.1186/s12943-026-02827-y
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Antibody–drug conjugates combined with immune checkpoint inhibitors in cancer: mechanisms, clinical evidence, and translational challenges

Yizhao Luo, 涂肇中, Zhiwei Ma, Yangchun Du et al.
1 links
Molecular Cancer
Cancer Immunotherapy and Biomarkers
article

Antibody–drug conjugates combined with immune checkpoint inhibitors in cancer: mechanisms, clinical evidence, and translational challenges

Yizhao Luo, 涂肇中, Zhiwei Ma, Yangchun Du, Lijun Li, Min Ling, Peng Luo
article en

Abstract

Immune checkpoint inhibitors (ICIs) have become an important component of cancer therapy, but primary resistance, acquired resistance, cold or immune-excluded tumor states, and immune-related adverse events continue to limit durable benefit. Antibody-drug conjugates (ADCs), while designed for targeted delivery of cytotoxic payloads, may also influence tumor cell death, antigen release, and local immune responses, providing a drug-design rationale for combination strategies with immunotherapy. Mechanistically, intratumoral ADC exposure and immune effects are shaped by the antibody, linker, payload, target internalization, and bystander effect, with implications for immunogenic cell death (ICD), the release of damage-associated molecular patterns (DAMPs), activation of cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling and Toll-like receptor (TLR) signaling, and remodeling of the tumor immune microenvironment (TIME). Clinical studies now span urothelial cancer, breast cancer, gynecologic malignancies, hematologic malignancies, lung cancer, and gastrointestinal cancers; interpretation of these findings requires attention to cancer type, target expression, payload class, treatment line, prior ICI exposure, and study design. Target heterogeneity, peripheral immune status, organ function, and comorbidities may further affect efficacy interpretation, toxicity attribution, and subsequent treatment selection. Further clinical translation should integrate biomarker development and patient stratification with resistance mechanisms, sequential therapy, quality of life, and treatment affordability, so that regimen design, patient selection, and safety management can be evaluated more clearly in prospective studies.

Molecular Cancer
University of Electronic Science and Technology of China (CN), Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (CN), Shantou University Medical College (CN), Zhujiang Hospital (CN), Southern Medical University (CN)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon